FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus

Proof‐of‐concept for clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase 2 BELIEVE study

(2021) D.F. Murrell et al.   BRITISH JOURNAL OF DERMATOLOGY

Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus

(2021) Maud Maho-Vaillant et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris

(2021) Victoria P. Werth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus

(2021) Ana-Luisa Stefanski et al.   CURRENT OPINION IN RHEUMATOLOGY

New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4

(2021) Anna Erdei et al.   IMMUNOLOGY LETTERS

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus

(2021) Victoria P. Werth et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial

(2021) M. Goebeler et al.   BRITISH JOURNAL OF DERMATOLOGY

Neonatal Fc receptor expression in lymphoid and myeloid cells in systemic lupus erythematosus

(2021) Ramdani Yanis et al.   LUPUS

CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors

(2020) Marie-Laure Golinski et al.   Frontiers in Immunology

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

(2020) Claire Mignard et al.   JAMA Dermatology

Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation

(2020) Fabian Junker et al.   Frontiers in Immunology

Novel Therapies for Pemphigus Vulgaris

(2020) Emily M. Altman   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay

(2020) Laurent Drouot et al.   Frontiers in Microbiology

Immunophenotyping in pemphigus reveals a TH17/TFH17 cell–dominated immune response promoting desmoglein1/3-specific autoantibody production

(2020) Julia Holstein et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

(2019) James F. Howard et al.   NEUROLOGY

Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease

(2019) Alice Cho et al.   Cell Reports

Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review

(2019) Gareth Edwards et al.   Frontiers in Immunology

Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris

(2019) Robert Pollmann et al.   Frontiers in Immunology

Pemphigus

(2019) Enno Schmidt et al.   LANCET

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen

(2019) Vivien Hébert et al.   Frontiers in Immunology

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

(2019) Adrian C. Newland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Neutrophil Extracellular Traps in Autoimmunity and Allergy: Immune Complexes at Work

(2019) Vanessa Granger et al.   Frontiers in Immunology

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

(2019) L. J. Blumberg et al.   Science Advances

Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands

(2018) Austin W. Boesch et al.   BIOTECHNOLOGY AND BIOENGINEERING

Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches

(2018) Robert Pollmann et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Circulating T FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity

(2018) Marios Koutsakos et al.   Science Translational Medicine

Targeting B Cells and Plasma Cells in Autoimmune Diseases

(2018) Katharina Hofmann et al.   Frontiers in Immunology

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

(2018) Peter Ulrichts et al.   JOURNAL OF CLINICAL INVESTIGATION

The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy

(2018) Malika Hale et al.   CURRENT OPINION IN IMMUNOLOGY

Large International Validation of ABSIS and PDAI Pemphigus Severity Scores

(2018) Vivien Hébert et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile

(2017) Christine W. Bruggeman et al.   JOURNAL OF IMMUNOLOGY

Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis

(2017) Huijie Yuan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

(2017) Pascal Joly et al.   LANCET

Mechanisms of Autoantibody-Induced Pathology

(2017) Ralf J. Ludwig et al.   Frontiers in Immunology

Peripheral CD19hi B cells exhibit activated phenotype and functionality in promoting IgG and IgM production in human autoimmune diseases

(2017) Zhicui Liu et al.   Scientific Reports

Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice

(2015) Shang-xue Yan et al.   ACTA PHARMACOLOGICA SINICA

Targeting the Neonatal Fc Receptor for Antigen Delivery Using Engineered Fc Fragments

(2014) W. Mi et al.   JOURNAL OF IMMUNOLOGY

The Role of FcRn in Antigen Presentation

(2014) Kristi Baker et al.   Frontiers in Immunology

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

(2013) N. Colliou et al.   Science Translational Medicine

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

(2012) P. Mark Hogarth et al.   NATURE REVIEWS DRUG DISCOVERY

Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones

(2010) I. Isnardi et al.   BLOOD

ELISA Testing of Anti–Desmoglein 1 and 3 Antibodies in the Management of Pemphigus

(2009) Claire Abasq et al.   ARCHIVES OF DERMATOLOGY

Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus Vulgaris

(2009) Angela Nagel et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE

(2008) Matilda W. Nicholas et al.   CLINICAL IMMUNOLOGY

Rituximab Exerts a Dual Effect in Pemphigus Vulgaris

(2008) Rüdiger Eming et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses

(2008) Hugo Mouquet et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

(2008) Dedee F. Murrell et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY